Reporter Molecule for Study of Alzheimer's Disease

Back to all technologies
Download as PDF
Researchers at Purdue University have developed pH-dependent fluorogenic amyloid-beta reporters for the study of Alzheimer's disease (AD). Microglial phagocytosis of amyloid-beta peptides is a critical step in the regulation of brain homeostasis during the initiation and progression of AD. Unlike common methods to study this phenomenon, this technology is specific for amyloid-beta and functions in live cells. The reporter, an isoform of human amyloid-beta tagged with a pH-dependent fluorogenic moiety, fluoresces only upon phagocytosis in the acidic intracellular phagosomes. It clearly differentiates between phagocytic and non-phagocytic cells within live human and nonhuman microglial cells. This technology promises to aid in the discovery of new therapeutics for AD.

-Facilitates live cell tracking of microglial phagocytosis
-Differentiates between phagocytic and non-phagocytic microglial cells

Potential Applications:
-Development of Alzheimer's Therapeutics

Publication: Monitoring phagocytic uptake of amyloid β into glial cell lysosomes in real time.
Sep 27, 2021
United States

Mar 27, 2020

Mar 29, 2019
United States
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486